[Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002243:Carbolines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D000068581:Tadalafil; D016896:Treatment Outcome
D002243:Carbolines; D003692:Delayed-Action Preparations; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human